Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff
Fourth Quarter Financial Performance: Medtronic reported fourth-quarter 2025 sales of $8.93 billion, exceeding expectations, with adjusted EPS of $1.62 and a year-over-year revenue increase of 3.9%. The cardiovascular segment saw significant growth, while diabetes revenue rose by 10.4%.
Business Separation Announcement: Medtronic plans to separate its Diabetes business into a standalone company within 18 months, aiming for improved margins and focused growth in high-margin markets, alongside an increase in cash dividends and adjusted EPS.
Trade with 70% Backtested Accuracy
Analyst Views on CVRD
About the author
PayPal Falls Despite Q2 Earnings Beating Estimates: ETFs in Focus
Earnings Report: PayPal reported second-quarter 2025 non-GAAP earnings of $1.40 per share, exceeding estimates and showing a 17.6% year-over-year increase, despite an 8% drop in stock price due to slowing transaction margin growth and a 5% decline in payment transactions.
Future Guidance: The company raised its full-year guidance for earnings and transaction margins, expecting non-GAAP earnings between $5.15 and $5.30 per share, while projecting transaction margin dollars to grow by 5-6%.
Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff
Fourth Quarter Financial Performance: Medtronic reported fourth-quarter 2025 sales of $8.93 billion, exceeding expectations, with adjusted EPS of $1.62 and a year-over-year revenue increase of 3.9%. The cardiovascular segment saw significant growth, while diabetes revenue rose by 10.4%.
Business Separation Announcement: Medtronic plans to separate its Diabetes business into a standalone company within 18 months, aiming for improved margins and focused growth in high-margin markets, alongside an increase in cash dividends and adjusted EPS.
PayPal Falls Despite Q2 Earnings Beating Estimates: ETFs in Focus
Earnings Report: PayPal reported second-quarter 2025 non-GAAP earnings of $1.40 per share, exceeding estimates and showing a 17.6% year-over-year increase, despite an 8% drop in stock price due to slowing transaction margin growth and a 5% decline in payment transactions.
Future Guidance: The company raised its full-year guidance for earnings and transaction margins, expecting non-GAAP earnings between $5.15 and $5.30 per share, while projecting transaction margin dollars to grow by 5-6%.
Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff
Fourth Quarter Financial Performance: Medtronic reported fourth-quarter 2025 sales of $8.93 billion, exceeding expectations, with adjusted EPS of $1.62 and a year-over-year revenue increase of 3.9%. The cardiovascular segment saw significant growth, while diabetes revenue rose by 10.4%.
Business Separation Announcement: Medtronic plans to separate its Diabetes business into a standalone company within 18 months, aiming for improved margins and focused growth in high-margin markets, alongside an increase in cash dividends and adjusted EPS.
